Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease

9 Aug 2018

Abstract excerpt

Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has become a target for specific epigenetic modifications related to cancer development. Overexpression of HDAC has been observed in several hematologic malignancies. Therefore, the observation that HDACs might play a role in various hematologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30096875
DOI: 10.3390/ijms19082337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative DiseasePMID 30096875Read ↗

Role of HDACs in normal and malignant hematopoiesisSemantic proximity Read ↗

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?Semantic proximity Read ↗

Histone deacetylase 6 in cancerSemantic proximity Read ↗

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cellsSemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

The therapeutic hope for HDAC6 inhibitors in malignancy and chronic diseaseSemantic proximity Read ↗

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human DiseasesSemantic proximity Read ↗

Mechanisms of HDACs in cancer developmentSemantic proximity Read ↗

Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimizationSemantic proximity Read ↗

HDAC6: Tumor Progression and BeyondSemantic proximity Read ↗

Targeting Histone Deacetylases 6 in Dual-Target Therapy of CancerSemantic proximity Read ↗

Histone deacetylases as therapeutic targets in hematologic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.